(S)-(-)-氨基-2-(1'-甲氧基-1'-甲基乙基)吡咯啉 | 118535-61-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (S)-(-)-氨基-2-(1'-甲氧基-1'-甲基乙基)吡咯啉
• 中文别名: (S)-(-)-1-氨基-2-(1'-甲氧基-1'-甲基乙基)吡咯烷；(S)-1-氨基-2-(二甲基甲氧基甲基)吡咯烷
• 英文名称: (S)-1-amino-2-(1'-methoxy-1'-methylethyl)pyrrolidine
• 英文别名: (S)-2-(2-Methoxypropan-2-yl)pyrrolidin-1-amine；(2S)-2-(2-methoxypropan-2-yl)pyrrolidin-1-amine
• CAS: 118535-61-8
• 化学式: C₈H₁₈N₂O
• 分子量: 158.244
• InChiKey: IPFWMHRLLPDMCC-ZETCQYMHSA-N

物化性质

• 沸点：
  66-70 °C (4.5 mmHg)
• 密度：
  0.989±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S37/39
• 危险类别码：
  R36/37/38

SDS

Name:	(S)-(-)-Amino-2-(1 -methoxy-1 -methylethyl )pyrrolidine Material Safety Data Sheet
Synonym:	SAE
CAS:	118535-61-8

Section 1 - Chemical Product MSDS Name:(S)-(-)-Amino-2-(1 -methoxy-1 -methylethyl )pyrrolidine Material Safety Data Sheet
Synonym:SAE

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
118535-61-8	(S)-(-)-Amino-2-(1'-methoxy-1'-methyle	100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Ingestion of large amounts may cause gastrointestinal irritation.
The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Do NOT get water inside containers. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed.
Avoid ingestion and inhalation. Do not allow contact with water. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Deep freeze (below -20C). Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 118535-61-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 67 - 70 deg C @ .10mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight:

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Moisture sensitive.
Conditions to Avoid:
Incompatible materials, moisture, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 118535-61-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(S)-(-)-Amino-2-(1'-methoxy-1'-methylethyl)pyrrolidine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 118535-61-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 118535-61-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 118535-61-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-(-)-氨基-2-(1'-甲氧基-1'-甲基乙基)吡咯啉 在 sodium hydride 、 2-(Phenylsulfonyl)-3-phenyloxaziridin 、 lithium diisopropyl amide 作用下， 反应 6.5h， 生成 [(S)-2-Benzyloxy-oct-(Z)-ylidene]-[(S)-2-(1-methoxy-1-methyl-ethyl)-pyrrolidin-1-yl]-amine
  参考文献：
  名称：

  通过金属化手性的羟基化反应，对映选择性地合成保护的α-羟基醛和酮

  摘要：

  高的对映体纯度的α-苄氧基醛和α-乙酰氧基酮4通过恶唑烷介导的手性氮杂酸酯的羟基化反应以良好的总收率制备。作为助剂，使用了新的脯氨酸衍生的肼试剂5。

  DOI：

  10.1016/s0040-4039(00)87901-0
• 作为产物：
  描述：

  Boc-L-脯氨酸甲酯 在 盐酸 、 lithium aluminium tetrahydride 、 sodium hydride 、 sodium nitrite 作用下， 以 四氢呋喃 、 乙醚 、 水 、 乙酸乙酯 、 mineral oil 为溶剂， 反应 10.0h， 生成 (S)-(-)-氨基-2-(1'-甲氧基-1'-甲基乙基)吡咯啉
  参考文献：
  名称：

  New Route for the Synthesis of Chiral Hydrazine SADP

  摘要：

  建立了一条合成(S)-1-氨基-2-(1-甲氧基-1-甲基乙基)吡咯烷（SADP）的简便路线。该路线涉及三个关键步骤，即 N-叔丁氧羰基脯氨酸酯的格氏加成（1）、氨基醇盐酸盐的亚硝基化（3）和 N-亚硝基吡咯烷醇基的 O-甲基化（4）。(S)-1-叔丁氧羰基-2-(1-羟基-1-甲基乙基)吡咯烷(2)与氢化钠反应也得到了(S)-1,1-二甲基-四氢吡咯并[1,2-c]恶唑-3-酮(6)。

  DOI：

  10.2174/157017812801264674

文献信息

• Palladium-Catalyzed Allylic Alkylation Using Chiral Hydrazones as Ligands
  作者：Takashi Mino、Masashi Shiotsuki、Nozomi Yamamoto、Tomoe Suenaga、Masami Sakamoto、Tsutomu Fujita、Masakazu Yamashita

  DOI：10.1021/jo0057001

  日期：2001.3.1

  Palladium-catalyzed asymmetric allylic alkylation of 1,3-diphenyl-2-propenyl acetate (4) with a dimethyl malonate-BSA-LiOAc system and its derivatives has been successfully carried out in the presence of a new chiral hydrazone ligands such as 2-(diphenylphosphino)benzaldehyde SAMP hydrazone (DPPBA-SAMP) (3a) in high yields with high enantioselectives.

  丙二酸丙二酯-BSA-LiOAc体系及其衍生物的钯催化1,3-二苯基-2-丙烯基乙酸乙酸酯（4）的不对称烯丙基烷基化反应及其衍生物已在新的手性配体如2-的存在下成功进行（二苯基膦基）苯甲醛SAMP（（DPPBA-SAMP）（3a）高收率和高对映选择性。
• Indeno [1,2-c]pyrazol-4-ones and their uses
  申请人：——

  公开号：US20010027195A1

  公开（公告）日：2001-10-04

  The present invention relates to the synthesis of a new class of indeno[1,2-c]pyrazol-4-ones of formula (I): 1 that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-9 and their regulatory subunits know as cyclins A-H. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.

  本发明涉及合成一种新类别的indeno[1,2-c]pyrazol-4-ones化合物，其化学式为(I):1，这些化合物是一类名为细胞周期依赖性激酶的酶的强效抑制剂，与催化亚基cdk1-9及其调节亚基cyclins A-H有关。本发明还提供了一种新颖的治疗癌症或其他增生性疾病的方法，即通过给予这些化合物中的一种或其药用可接受的盐形式的治疗有效剂量。另外，可以通过给予本发明化合物之一与一种或多种其他已知的抗癌或抗增生剂的治疗有效组合来治疗癌症或其他增生性疾病。
• Regio- and Enantioselective Alkylation of a N-Protected Pyrrolidin-3-one Using Enders’ Chiral Hydrazone Method: A Key Step Towards a New Asymmetric Total Synthesis of (-)-Quinocarcin and Related Analogues
  作者：Jean-Charles Quirion、Uwe Schneider、Xavier Pannecoucke

  DOI：10.1055/s-2002-34224

  日期：——

  The synthesis of C-4-alkylated pyrrolidin-3-one 5 was achieved by regio- and diastereoselective alkylation of chiral hydrazone 8 with electrophile 7 followed by selective deprotection. Highly functionalised compound 5 is the first key intermediate in our approach towards a new asymmetric total synthesis of (-)-quinocarcin (1) and related structural analogues 2 and 3.

  C-4-烷基化吡咯烷-3-one 5 的合成是通过手性腙8 与亲电子试剂7 的区域选择性和非对映选择性烷基化，然后选择性脱保护来实现的。高度官能化的化合物 5 是我们实现 (-)-喹诺酮 (1) 和相关结构类似物 2 和 3 的新型不对称全合成方法中的第一个关键中间体。
• Palladium-catalyzed asymmetric allylic substitution using planar chiral hydrazone ligands
  作者：Takashi Mino、Teruhiro Ogawa、Masakazu Yamashita

  DOI：10.1016/s0022-328x(02)02102-2

  日期：2003.1

  Palladium-catalyzed asymmetric allylic alkylation of 1,3-diphenyl-2-propenyl acetate (3) with a dimethyl malonate–BSA–LiOAc system has been successfully carried out in the presence of planar chiral phosphine-hydrazone ligands such as 2a in good yields with good enantioselectivities (up to 96% ee).

  在平面型手性膦-配体（例如2a）的存在下，成功地进行了钯催化的1,3-二苯基-2-丙烯基乙酸乙酸酯（3）的钯不对称烯丙基烷基化反应（3），收率良好具有良好的对映选择性（高达96％ee）。
• Palladium-catalyzed Asymmetric Allylic Alkylation Using Chiral Pyridyl-hydrazone Ligands
  作者：Takashi Mino、Yoshiaki Shirae、Toru Yajima、Masami Sakamoto、Tsutomu Fujita

  DOI：10.3987/com-06-10723

  日期：——

  Palladium-catalyzed asymmetric allylic alkylation of 1,3-diphenyl-2-propenyl acetate (5) with a dimethyl malonate-BSA-LiOAc system has been successfully carried out in the presence of chiral pyridyl-hydrazone ligands such as 2c with moderate enantioselectivities (up to 67% ee).

  钯催化的 1,3-二苯基-2-丙烯基乙酸酯 (5) 与丙二酸二甲酯-BSA-LiOAc 体系在手性吡啶基腙配体（如 2c）存在下成功地进行了不对称烯丙基烷基化反应，具有中等的对映选择性（高达 67% ee)。